ERBB2 and cancer: Their ratiometric SERS aptasensor (for HER2 and EpCAM), as opposed to conventional SERS, demonstrated high accuracy for target identification (considering the heterogeneity of cancer exosomes) and ultrahigh sensitivity for the early detection of cancer in patients and without any need for nucleic acid amplification.